NCT03019640
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +17 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Recurrent Diffuse Large B-Cell Lymphoma
Explore clinical trials studying Recurrent Diffuse Large B-Cell Lymphoma. Study availability and eligibility vary by location and protocol.
60 public trials
18 recruiting studies
Recurrent Diffuse Large B-Cell Lymphoma trial results
NCT02405078
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT01865617
- Conditions
- CD19-Positive Neoplastic Cells Present, Chronic Disease, Disease Attributes, +32 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT01527045
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Blood Protein Disorders, +57 more
- Locations
-
- Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT01251575
- Conditions
- Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, +67 more
- Locations
-
- Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
- Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
- VA Puget Sound Health Care System Seattle, Washington, United States
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Completed
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
NCT00880815
- Conditions
- CD20 Positive, Chronic Disease, Chronic Lymphocytic Leukemia, +28 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Completed
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
NCT01897012
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +36 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT02219737
- Conditions
- CD20 Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- Memorial Sloan-Kettering Cancer Center New York, United States
NCT07098364
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +20 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States